Diabetes affects Ͼ285 million people globally (112% increase since 1995); and this number is projected to increase to almost 440 million by 2025 (1, 2 ) . Correlation between hyperglycemia and complications such as retinopathy and neuropathy was established by the Diabetes Control and Complications Trial (DCCT) 4 (1983-1993) (3, 4 ) , and the cardiovascular disease relationship was established by the Epidemiology of Diabetes Interventions and Complications study (1993 onward) (5 ) . Because these complications are the leading causes of morbidity and mortality in people with diabetes and are reduced when hemoglobin A 1c (Hb A 1c ) is Ͻ7%, stringent glycemic monitoring and control is essential (6 ) . Hb A 1c measurement is used with other glucose tests in screening for diabetes (7 ) , and Hb A 1c monitoring influences clinical treatment decisions.
Hb A 1c is the amino-terminal nonenzymatic glycation (on amino-terminal valine residues of the ␤-chain) product of Hb A and depends on the concentration of blood glucose and the lifespan of circulating red blood cells (approximately 120 days) (8, 9 ) . Hb A 1c levels (expressed as a percentage of total Hb A) reflect long-term blood glucose concentrations and thus the efficacy of glycemic control (10, 11 ) over the prior 2-3 months, 50% of which is representative of the previous month, 25% of the previous 2 months, and 25% of the previous 3 months ( 12, 13 ) .
Whole blood (WB) venous samples collected by venipuncture into EDTA Vacutainer Tubes are used most commonly for Hb A 1c measurement, and transportation to a central laboratory in large-scale population-based studies is costly. The stability of Hb A 1c is questionable when there are variable and extended periods between collection and analysis (14, 15 ) . Blood sample collection onto filter paper (FP) has been implemented in epidemiologic studies (16 ) and significantly decreases transportation costs and limits the challenges of shipping dangerous goods in large-scale multinational population studies. Previous work showed that Hb A 1c FP samples are stable and provide reliable, reproducible values after 5-7 days at room temperature, 10 days at 4 -6°C, and several months at Ϫ70°C (17) (18) (19) (20) . This investigation examined FP collected in 78 countries representing every region of the world for suitability to measure Hb A 1c .
Materials and Methods

ANALYTICAL INSTRUMENTS AND Hb A 1c MEASUREMENT
Three Bio-Rad Variant II (www.biorad.com) ionexchange HPLC instruments were used with the 6.5-min (␤-thalassemia method) Variant II HbA 2 /HbA 1c Dual Program to measure Hb A 1c in WB and extracted FP samples. Prior investigation using the 1.5-min (Turbo) and 3-min Variant II programs resulted in insufficiently separated chromatograph elution peaks. The instrument autoinjects samples into an analytical cartridge, which separates hemoglobins on the basis of ionic interaction with the cartridge material. Eluted hemoglobins pass through the detection station, where changes in absorbance are read at 415 nm (background corrected at 690 nm). Clinical data management software analyzes the raw absorbance data and uses an exponentially modified gaussian algorithm to calculate areas for Hb A 2 , Hb F, and Hb A 1c .
Hb A 1c was measured from WB and from drops of the same WB applied to FP. The Variant II instruments were calibrated daily at the beginning of the first analytical run with dual-level (␤-Thal CalSet; Bio-Rad) standardized to the DCCT. Bio-Rad A 2 /F controls were tested at the beginning of each run, and in-house FP QC samples (blotted from WB and stored at Ϫ70°C) were tested at the beginning and end of each analytical run. The FP and WB samples and Bio-Rad A 2 /F controls were prediluted in 1 mL Bio-Rad hemolyzing buffer. A 3/16-inch disk was punched from each FP sample into the extraction buffer; 30 min was allowed for blood to elute into solution at room temperature, which was followed by removal of the disk. Five microliters of each WB sample and Bio-Rad control was added to 1 mL of hemolyzing buffer. Vials were inverted to mix thoroughly before analysis. Each resulting chromatograph was initially screened by using acceptance/repeat/rejection criteria developed within the Clinical Research and Clinical Trials Laboratory (CRCTL) ( Table 1) .
INSTRUMENT/METHOD VALIDATION
Intraassay precision. Intraassay precision was determined by using in-house FP samples stored at Ϫ70°C (normal approximately 5.6% and high approximately 8.0%). Ten FP hemolysates of each level were prepared and analyzed on each of 3 instruments on each of 3 days. Precision was determined as CV%: [(SD/ mean) ϫ 100], calculated from the mean and SD of each sample on each instrument each day. Linearity. Linearity was evaluated by using 22 WB samples, each prepared as 10 dilutions with homologous plasma (see Table 1 in the online Data Supplement) to determine whether %Hb A 1c is affected by total hemoglobin concentration. Each dilution of each sample was blotted onto FP, air-dried, frozen overnight at Ϫ70°C, thawed, and analyzed.
WB VS FP METHOD COMPARISON
Eighty-five routine clinical WB specimens were selected on the basis of an initial Hb A 1c result, with emphasis on the clinically relevant Hb A 1c range (approximately 5.5% to 8.5%), stored at 4°C, blotted on FP, and analyzed within 96 h of sample collection. Each FP and matching WB sample were analyzed on the same run. Passing-Bablok and Bland-Altman method comparison analyses were performed to evaluate bias between sample types.
FP STABILITY
FP QC samples prepared in-house in the normal (approximately 5.6% and 5.3%) and high (approximately 9.0% and 9.7%) Hb A 1c range were stored at Ϫ70°C and tested at the beginning and end of every analytical run over approximately 3 years. Sample stability was assessed by using Deming linear regression and calculated as the CV% of all measures on each instrument for each QC.
STATISTICAL METHODS
Passing-Bablok and Deming linear regression analyses and Bland-Altman bias testing were performed in Analyse-it Standard Edition for Microsoft Excel (Analyse-it Software, www.analyse-it.com). KruskalWallis, Dunns, and further Bland-Altman testing were performed by using GraphPad Prism 5 (GraphPad Software, www.graphpad.com). Statistical significance was defined as P Ͻ 0.05.
SAMPLE COLLECTION FOR EPIDEMIOLOGIC STUDIES
Approximately 700 collection centers in 78 countries followed standardized sample collection and handling protocols provided by the CRCTL for both the INTERHEART (a study of the effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries) (21 ) 
MORPHOMETRIC ANALYSIS OF BORDERLINE CHROMATOGRAPHS
In an attempt to improve objectivity in the evaluation of peak integration, 100 chromatographs of varying quality were reviewed 3 times by 5 operators (3 experienced, 2 naive). Chromatographs were classified on the basis of acceptability of Hb A 1c peak integration: those defined by Ն4 operators as accepted or rejected were classified accordingly, and images were deemed borderline if multiple operators did not consistently accept/reject a chromatograph when shown it 3 times in a blinded trial. This resulted in a subset of 25 "borderline" chromatographs. Morphometric analysis of this subset (Adobe Photoshop 7, www.adobe.com) determined the area of the integration peak, nonintegrated area (between the integration peak and the elution peak), and the total area under the elution peak. Area measurements were restricted to the region within the Hb A 1c retention time window (defined by the instrument as 0.83 Ͻ t Ͻ 1.03 min on the x axis). Maximum integration peak height and total width of the bellshaped curve (trough-to-trough) were also measured. Subsequent analysis revealed that the 25 chromatographs consistently possessed poorly integrated Hb A 1c peaks. From these, 14 borderline chromatographs displaying only the "poor integration" trait (without other confounding traits described in Table 1) were selected to further quantify this subjective feature. To estimate interchromatograph error associated with the morphometric analysis, area measurements were repeated 10 times on a single chromatograph and CV% was calculated for integrated, nonintegrated, and total areas.
Results
BIO-RAD VARIANT II/6.5-MIN PROGRAM VALIDATION
In-house prepared FP samples at both normal (approximately 5.6%) and high (approximately 8.0%) Hb A 1c values yielded excellent intraassay (CV% Յ1.84% and 1.29%, respectively) and interassay (CV% Յ1.60% and 1.23%, respectively) precision. Interassay precision testing across all QC samples (on all instruments) generated CV% of Յ2.00%. Table 2 provides a summary indicating that all data from all 3 instruments are consistent with excellent performance. The instruments performed well, meeting the intralaboratory imprecision specifications recommended by Sacks et al. (23 ) and Bio-Rad (Ͻ3% and Յ4%, respectively). Accuracy assessment from NGSP accreditation monitoring across the Hb A 1c range of 4.45% to 13.5% revealed an increasing negative bias (range of 0.02% to Ϫ0.73%; fractional error range of 0.0034 to Ϫ0.0602; see Table 2 in the online Data Supplement) with DCCT-referenced Hb A 1c values. When focused on the clinically significant range (Hb A 1c Յ8.5%), the mean negative bias was Ϫ0.1% (fractional error ϭ Ϫ0.0128). This level of accuracy meets the level I standard for NGSP accreditation [accuracy, lower 95%, upper 95% (Ϯ0.75%)].
Readable area range experimentation demonstrated consistently acceptable Hb A 1c results and chromatograph elution patterns when total area of analysis was between 0.8 and 5.5 ϫ 10 6 V/s (compared to BioRad's suggested range of 1.5-3.5 ϫ 10 6 V/s). Linearity testing of FP blotted with WB samples prediluted with homologous plasma yielded Deming regression equations with a mean slope of Ϫ3.83 ϫ 10 Ϫ3 (range Ϫ5.7 ϫ 10 Ϫ2 to 7.0 ϫ 10
Ϫ2
). The mean fractional error [(%Hb A 1c of diluted sample Ϫ %Hb A 1c of neat sample)/%Hb A 1c of neat sample] between each dilution and its neat sample was Ϫ0.0026 (mean absolute fractional error of 0.0108) with a maximum of 0.0488, indicating that sample values were virtually unaffected by dilutions as great as 2 in 5.
WB VS FP METHOD COMPARISON
All chromatographs for WB and matching FP were acceptable according to the criteria in Table 1 (Fig. 1A) with a slight negative bias [percent difference ϭ Ϫ1.66% (1.94%)] (Fig. 1B) . However, when the comparison of FP to WB was restricted to the 51 samples in the clinically significant range (Յ8.5%), linear regression indicated less negative bias [(FP Hb A 1c ) ϭ 
FP STABILITY
In-house FP QC samples stored at Ϫ70°C showed virtually no degradation over 3 years (CV% 1.72-2.73) (see Table 3 in the online Data Supplement). Deming linear regression analysis for each control yielded slopes with a range of Ϫ1.08 ϫ 10 Ϫ4 to 7.81 ϫ 10 Ϫ4 (Fig. 2) . Chromatographs from these samples had similar elution patterns and consistent total area counts.
LARGE-SCALE STUDY APPLICABILITY
To validate the applicability of the decision rules ( 
MORPHOMETRIC ANALYSIS OF BORDERLINE CHROMATOGRAPHS
Morphometric analysis of 42 chromatographs (14 accepted, 14 borderline, and 14 rejected) revealed striking differences between these 3 groups in Hb A 1c peak integration relative to the total area beneath the elution peak (Fig. 3) . Accepted images had significantly lower (P Ͻ 0.01) percentages of nonintegrated Hb A 1c peak area [20.54% (12.17%)] than high mean percent nonintegrated areas [44.16% (7.28%)] for those classified as rejected (Fig. 3) . The mean percent nonintegrated area for the "borderline" subset of chromatographs was intermediate [35.40% (3.28%)] to and significantly different (P Ͻ 0.05) from the accepted and rejected groups. The variation for 10 measurements of total integrated, nonintegrated, and total area on a single chromatograph was minimal (CVs Յ1.68%), indicating the automated area-counting tool provided reproducible area (pixel) counts and is a valid means for data acquisition and assessment of integration (see Table 4 in the online Data Supplement). The criterion "inadequate separation" could not be quantified by using the morphometric tool. The spectrum for the degree of separation criteria is illustrated in Fig. 4 by chromatographs of 3 different specimens. The 3 chromatographs exhibit distinct differences in the degree of labile Hb A 1c (LA 1c ) and Hb A 1c separation, such that the result illustrated in Fig. 4A is acceptable, the result in 4B would be repeated/reevaluated, and the result in 4C would be rejected according to the criteria listed in Table 1 .
Discussion
Numerous methods exist for the determination of WB Hb A 1c , including column chromatography, electrophoresis and isoelectric focusing, and colorimetric and immunoassays (24 -26 ) . Ion-exchange HPLC methods allow Hb A 1c determination without interference from its Schiff base (LA 1c ) and can be used for variant screening (27, 28 ) . Automated HPLC instruments allow rapid and reproducible analysis of samples, appropriate for large population-based studies.
Previous evaluation of the Bio-Rad Variant II yielded intra-and interassay precision of Ͻ5% (28 ) and demonstrated the utility and validity of the dual program for measurement of Hb A 1c from routine clinical WB samples (29, 30 ) . We identified 2 limitations affecting our large-scale epidemiologic studies using FP samples: a high repeat rate for samples collected under variable conditions and a negative bias in the high end (Ն8.5 %Hb A 1c ) of the DCCT range for FP samples relative to WB.
Earlier (17 ) and more recent (31 ) reports indicate that Hb A 1c analysis using FP samples yields comparable results to those acquired using WB. Our study extends these findings and validates the use of FP samples collected under field conditions in 78 countries from patients enrolled in large, multinational, populationbased studies. The Bio-Rad Variant II instrument, using the 6.5-min (␤-thalassemia) Variant II HbA 2 / HbA 1c Dual Program, is a superior method for Hb A 1c measurement in a central laboratory for FP blotted with WB.
Our data quantify the Bio-Rad Variant II 6.5-min (␤-thalassemia) HbA 2 /HbA 1c Dual Program accuracy, precision, and robustness. Intraassay precision was consistently Ͻ2%, and Ͼ90% of interassay CV% values were Ͻ2%. Dilution experiments indicated consistent and reproducible %Hb A 1c results across a broad range of sample dilutions, and the reportable total area range (V/s) on the instrument accommodated both dilute and concentrated FP eluates, as reported by Higgins et al. (28 ) . This is important because our experience with FP collection on a global scale indicates some WB samples settle before blotting on FP, resulting in a concentrated sample drawn from the erythrocytes in the bottom of the tube, or a dilute sample drawn near the top of the tube.
NGSP accreditation monitoring of the 6. (17 ) . Our data indicate that FP blotted with WB and stored at Ϫ70°C maintained sample integrity and yielded CVs Յ2.73% over approximately 3 years, supporting research facilities and/or biorepositories storing samples at Ϫ70°C over many years.
Large-scale/multinational population-based studies present difficulties not normally encountered during routine clinical analysis. Although standardized protocols are provided to sample collection sites, samples collected in global studies may be subjected to potentially degenerative effects of harsh preanalytical conditions. Nevertheless, the Bio-Rad Variant II generated reportable values for approximately 83% and approximately 86% for INTERHEART and CURE, respectively, of 15 855 FP samples on the first test. INTERHEART samples were frequently rejected for issues related to the quality of sample preparation and preanalytical sample degradation (i.e., Hb A 1c shouldering, high LA 1c , very low area counts), whereas CURE specimens were rejected for instrument pro- Blinded interoperator chromatograph analysis showed that ambiguous criteria were those that lacked numerical definitions (Table 1) . To refine these subjective repeat/rejection criteria, morphometric analysis of accepted, rejected, and borderline chromatographs revealed significant differences (P Ͻ 0.05) in the percent nonintegrated area (nonintegrated area/total area) between the 3 groups of chromatographs. Those classified as accepted were consistently better integrated (mean 20.54% nonintegrated) than the borderline (35.40%) or rejected (44.16%) chromatographs. The error associated with the morphometric analysis yielded CVs of Յ1.68% for area measurements. It was not possible to quantify inadequate separation, the other qualitative rejection criterion, although a clear visual distinction between accepted, borderline, and rejected elution patterns is present (Fig. 4 and Fig. 2 in the online Data Supplement).
In summary, the data presented in this report validate both the collection of WB on FP for Hb A 1c determination in large-scale population studies and testing of these FP samples on the Bio-Rad Variant II using the 6.5-min (␤-thalassemia) Variant II HbA 2 / HbA 1c Dual Program in a level I NGSP-accredited laboratory. The negative bias in FP results compared to WB is negligible and does not affect clinical decisions (Fig. 1) . The utility of FP collection under field conditions makes worldwide sample collection for Hb A 1c testing feasible. However, it is imperative that personnel in the field receive adequate training and understand the importance of consistent collection, handling, freezer storage, and shipment practices, to avoid high nonreportable rates at analysis. In addition, we anticipate that our approach to the quantification and visual representation of qualitative and highly subjective chromatograph traits deemed "reasons for repeat/ rejection" will reduce interoperator decision-making variability and improve the analysis and reporting of Hb A 1c values.
